comparemela.com

Latest Breaking News On - Augmedix - Page 8 : comparemela.com

Augmedix signs up for foodpanda s corporate services

Healthcare technology company Augmedix has signed up for on foodpanda’s corporate platform, foodpanda for business.

Comparing Augmedix (AUGX) & Its Rivals

Augmedix (OTCMKTS:AUGX – Get Rating) is one of 228 public companies in the “Business services, not elsewhere classified” industry, but how does it weigh in compared to its competitors? We will compare Augmedix to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership. Earnings & Valuation […]

Augmedix (OTCMKTS:AUGX) vs Grab (NASDAQ:GRAB) Critical Comparison

Augmedix (OTCMKTS:AUGX – Get Rating) and Grab (NASDAQ:GRAB – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Insider & Institutional Ownership 59.0% of Augmedix shares are owned by institutional […]

Augmedix (AUGX) versus Its Rivals Head-To-Head Contrast

Augmedix (OTCMKTS:AUGX – Get Rating) is one of 227 publicly-traded companies in the “Business services, not elsewhere classified” industry, but how does it compare to its peers? We will compare Augmedix to similar businesses based on the strength of its valuation, analyst recommendations, risk, dividends, earnings, profitability and institutional ownership. Insider and Institutional Ownership 59.0% […]

Augmedix (OTCMKTS:AUGX) Upgraded to Buy at Zacks Investment Research

Augmedix (OTCMKTS:AUGX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The firm currently has a $2.25 price target on the stock. Zacks Investment Research‘s target price points to a potential upside of 6.64% from the […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.